文献速递肾小球疾病

糖皮质激素治疗肾小球疾病:陷阱与要点

Glucocorticoids in the Treatment of Glomerular Diseases: Pitfalls and Pearls.
PubMed 文献 · Clin J Am Soc Nephrol · 2018-02-23

本文综述糖皮质激素在肾小球疾病治疗中的药理机制、副作用及临床应用要点。糖皮质激素通过基因组和非基因组效应发挥抗炎和免疫抑制作用,但治疗指数低,需注意时间与剂量依赖性副作用。合成糖皮质激素仍是多种肾小球疾病的基础治疗,但在C3肾小球病中获益有限,在适应不良性局灶性肾小球硬化中可能有害。

要点

  • 糖皮质激素仍是多种肾小球疾病的基础治疗,但疗效取决于疾病类型、严重程度、给药时机、剂量和疗程。
  • 预防或减轻副作用措施包括晨间单次给予短效糖皮质激素、饮食咨询、增加体力活动、频繁监测及根据临床状况调整剂量。
  • 糖皮质激素在C3肾小球病中获益有限,在适应不良性局灶性肾小球硬化中可能有害。

核心结论

  • 糖皮质激素治疗指数低,需权衡疗效与时间及剂量依赖性副作用。
  • 合成糖皮质激素仍是多种肾小球疾病的基础治疗,但并非对所有肾小球疾病均有益。

研究设计与样本

  • 综述,未报告检索范围及样本量。

主要发现

  • 糖皮质激素通过基因组效应(反式激活和反式抑制)及可能由膜受体介导的非基因组效应发挥抗炎和免疫抑制作用。
  • 糖皮质激素受体也表达于足细胞,实验数据提示糖皮质激素可能保护足细胞免受损伤。
  • 糖皮质激素在C3肾小球病中获益有限,在适应不良性局灶性肾小球硬化中可能有害。
  • 糖皮质激素疗效取决于肾小球疾病类型和严重程度、给药及时性、剂量及疗程。
  • 糖皮质激素过度使用可导致严重毒性,剂量过低和疗程过短可导致假性激素抵抗。

临床怎么用

  • 采用晨间单次给予短效糖皮质激素、饮食咨询、增加体力活动、频繁监测及根据临床状况调整剂量以预防或减轻副作用。
  • 根据肾小球疾病类型和严重程度、给药时机、剂量及疗程个体化使用糖皮质激素。
  • 避免在C3肾小球病和适应不良性局灶性肾小球硬化中不合理使用糖皮质激素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Glucocorticoids exert anti-inflammatory and immunosuppressive activities by genomic and nongenomic effects. The classic genomic effects are mediated by cytosolic glucocorticoid receptors that can upregulate the expression of anti-inflammatory proteins in the nucleus (transactivation) or repress the translocation of proinflammatory transcription factors from the cytosol into the nucleus (transrepression). The nongenomic effects are probably mediated by membrane glucocorticoid receptors. Glucocorticoid receptors are expressed also in podocytes and experimental data suggest that glucocorticoids may protect from podocyte injury. Glucocorticoids have a low therapeutic index and may exert a number of time-dependent and dose-dependent side effects. Measures to prevent or attenuate side effects include single-morning administration of short-acting glucocorticoids, dietetic counseling, increasing physical activity, frequent monitoring, and adapting the doses to the clinical conditions of the patient. Synthetic glucocorticoids, either given alone or in combination with other immunosuppressive drugs, are still the cornerstone therapy in multiple glomerular disorders. However, glucocorticoids are of little benefit in C3 glomerulopathy and may be potentially deleterious in patients with maladaptive focal glomerulosclerosis. Their efficacy depends not only on the type and severity of glomerular disease, but also on the timeliness of administration, the dosage, and the duration of treatment. Whereas an excessive use of glucocorticoids can be responsible for severe toxicity, too low a dosage and too short duration of glucocorticoid treatment can result in false steroid resistance.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Ponticelli C, Locatelli F. Glucocorticoids in the Treatment of Glomerular Diseases: Pitfalls and Pearls. Clin J Am Soc Nephrol. 2018. PMID: 29475991. doi:10.2215/CJN.12991117

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。